$167 Million is the total value of Abingworth LLP's 13 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was 38.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RNA | Prosensa | $116,511,000 | +122.4% | 6,213,924 | 0.0% | 33.09% | +5.7% | |
| PRTK | New | Paratek | $49,974,000 | – | 1,301,413 | +100.0% | 14.19% | – |
| SIEN | New | Sientra | $36,877,000 | – | 2,199,012 | +100.0% | 10.47% | – |
| PTLA | Portola | $26,357,000 | +12.0% | 930,682 | 0.0% | 7.49% | -46.8% | |
| SUPN | Supernus | $23,927,000 | -4.4% | 2,879,328 | 0.0% | 6.80% | -54.6% | |
| EVAR | Buy | Lombard Medical | $22,056,000 | -14.0% | 3,473,452 | +3.6% | 6.26% | -59.1% |
| PRTO | New | Proteon | $20,340,000 | – | 2,017,872 | +100.0% | 5.78% | – |
| DRNA | Dicerna | $19,423,000 | +29.2% | 1,182,196 | 0.0% | 5.52% | -38.6% | |
| CEMP | Cempra | $16,779,000 | +114.3% | 714,285 | 0.0% | 4.77% | +1.8% | |
| AMRN | Amarinspons adr | $7,847,000 | -11.0% | 8,087,486 | 0.0% | 2.23% | -57.7% | |
| RGLS | Regulus | $5,247,000 | +134.0% | 327,350 | 0.0% | 1.49% | +11.2% | |
| ZGNX | Zogenix | $3,176,000 | +18.2% | 2,335,218 | 0.0% | 0.90% | -43.8% | |
| HPTX | Hyperion | $1,499,000 | -4.9% | 62,500 | 0.0% | 0.43% | -54.8% | |
| OGXI | Oncogenex Pharma | $1,352,000 | -15.5% | 603,740 | 0.0% | 0.38% | -59.9% | |
| ANTH | Anthera | $679,000 | -18.4% | 437,994 | 0.0% | 0.19% | -61.2% | |
| ZLCS | New | Epirus Biopharma | $44,000 | – | 7,896 | +100.0% | 0.01% | – |
| EPRSQ | Exit | Epirus Biopharma | $0 | – | -7,896 | -100.0% | -0.03% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Abingworth Management LTD #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-NT | 2024-05-03 |
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
| 13F-HR | 2023-02-10 |
| 4 | 2023-01-31 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.